Issue navigation
Volume 2, Issue Supplement_1, July 2020
Special Issue: A Contemporary Landscape of the Clinical and Biological Research in Neurofibromatosis Type 1
Treatment and surgical factors associated with longer-term glioblastoma survival: a National Cancer Database study
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages 1–10, https://doi.org/10.1093/noajnl/vdaa070
Supplement Articles
Continuing Medical Education Information
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages i1–i7, https://doi.org/10.1093/noajnl/vdaa072
Special issue: a contemporary landscape of the clinical and biological research in neurofibromatosis type 1
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages i8–i12, https://doi.org/10.1093/noajnl/vdaa045
New insights into the neurofibroma tumor cells of origin
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages i13–i22, https://doi.org/10.1093/noajnl/vdz044
After Nf1 loss in Schwann cells, inflammation drives neurofibroma formation
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages i23–i32, https://doi.org/10.1093/noajnl/vdz045
The impact of host immune cells on the development of neurofibromatosis type 1: The abnormal immune system provides an immune microenvironment for tumorigenesis
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages i33–i39, https://doi.org/10.1093/noajnl/vdz037
Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages i40–i49, https://doi.org/10.1093/noajnl/vdz047
Genetics of human malignant peripheral nerve sheath tumors
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages i50–i61, https://doi.org/10.1093/noajnl/vdz049
KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages i62–i74, https://doi.org/10.1093/noajnl/vdz061
Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages i75–i84, https://doi.org/10.1093/noajnl/vdz026
Brain tumors in neurofibromatosis type 1
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages i85–i97, https://doi.org/10.1093/noajnl/vdz040
NF1-like optic pathway gliomas in children: clinical and molecular characterization of this specific presentation
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages i98–i106, https://doi.org/10.1093/noajnl/vdz054
Management of cutaneous neurofibroma: current therapy and future directions
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages i107–i116, https://doi.org/10.1093/noajnl/vdz034
Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromass
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages i117–i123, https://doi.org/10.1093/noajnl/vdz050
Abdominal neoplastic manifestations of neurofibromatosis type 1
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages i124–i133, https://doi.org/10.1093/noajnl/vdaa032
Clinical trial design in neurofibromatosis type 1 as a model for other tumor predisposition syndromes
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages i134–i140, https://doi.org/10.1093/noajnl/vdaa017
Quality of life in patients with neurofibromatosis type 1 and 2 in Canada
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages i141–i149, https://doi.org/10.1093/noajnl/vdaa003
Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations
Neuro-Oncology Advances, Volume 2, Issue Supplement_1, July 2020, Pages i150–i158, https://doi.org/10.1093/noajnl/vdaa037
